Skip to content

Study · Animal study (in vivo) · rat · 2005

4 results

Feeding response to melanocortin agonist predicts preference for and obesity from a high-fat diet.

Chandler PC, Viana JB, Oswald KD, Wauford PK, Boggiano MM

Physiology & behavior1 Jun 2005Cited by 30 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In chow-fed rats, central melanotan II suppressed food intake more in diet-induced obesity-prone rats than in obesity-resistant rats.

    In plain wordsIn rats, melanotan II given into the brain cut food intake more in obesity-prone rats than in obesity-resistant rats.

    Outcome
    DecreaseAnorectic response to MTII in chow-fed rats
    Study

    ratn: not reported in source

    DIO-P and DIO-R rats on chow
    Comparator
    DIO-R rats
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · centralAs given in this study (rat).

    Source sentences

    Summary
    We found that prior to developing obesity and while still maintained on chow, acute, central administration of MTII, an MC agonist, produced a greater anorectic response in DIO-P rats than in DIO-R rats.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In obesity-resistant rats, melanotan II suppressed food intake significantly more after 5 days of exclusive high-fat feeding than on chow.

    In plain wordsIn obesity-resistant rats, melanotan II cut food intake more after 5 days of a high-fat diet than it did on chow.

    Outcome
    DecreaseSuppression of intake by MTII after 5 days of high-fat diet in DIO-R rats
    Study

    ratn: not reported in source

    DIO-R rats
    Comparator
    Same rats on chow
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · centralAs given in this study (rat).

    Source sentences

    Summary
    However, after only 5 days of exclusive HF feeding, the DIO-R rats had significantly greater suppression of intake after MTII treatment than they did when maintained on chow.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    After 5 days of high-fat diet, obesity-prone rats responded much less to melanotan II than obesity-resistant rats.

    In plain wordsIn rats on a high-fat diet, obesity-prone rats responded much less to melanotan II than obesity-resistant rats.

    Outcome
    DecreaseResponsiveness to MTII after 5 days of high-fat diet, DIO-P versus DIO-R
    Study

    ratn: not reported in source

    DIO-P and DIO-R rats
    Comparator
    DIO-R rats
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · centralAs given in this study (rat).

    Source sentences

    Summary
    In addition, the DIO-P rats were much less responsive to MTII treatment than the DIO-R rats after only 5 days of the HF diet.
  4. 04AnimalAnimal study (in vivo)Other

    In rats on a high-fat diet, melanotan II-induced anorexia correlated negatively with body weight gained on the diet.

    In plain wordsIn rats on a high-fat diet, a stronger food-intake response to melanotan II was linked to less weight gain.

    Outcome
    Not applicableCorrelation of MTII-induced anorexia with weight gain on high-fat diet
    Study

    ratn: not reported in source

    Rats on high-fat diet
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · centralAs given in this study (rat).

    Source sentences

    Summary
    In fact, MTII-induced anorexia during HF feeding correlated negatively with body weight gained on the HF diet.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.